期刊文献+

绝经早期妇女长期周期联合应用经皮雌二醇与口服孕激素的阴道出血情况 被引量:2

The vaginal bleeding pattern in early postmenopausal women with long-term combined cyclic regimen of percutaneous estradiol and oral progestin
下载PDF
导出
摘要 目的探讨中国绝经早期妇女长期周期联合应用经皮雌二醇与口服孕激素的出血情况。方法开放性随机前瞻性研究7年。周期联合应用雌孕激素,雌激素为经皮雌二醇(E_2)凝胶,口服孕激素为微粉化天然黄体酮(MP)与甲羟孕酮(MPA)。60例绝经早期(1~5年)妇女随机分为4组:G1(E_2 1.5 mg/d+MP100 mg/d);G2(E_2 1.5 mg/d+MPA 2 mg/d);G3(E_2 0.75 mg/d+MP100 mg/d);G4(E_2 0.75 mg/d+MPA 2 mg/d)。每周期连用25 d,停药5 d。记录出血日记,包括出血日、出血天数和出血量;分别将出血天数≤7 d且血量≤1.0、出血天数≤7 d且血量>1.0、出血天数>7 d且血量≤1.0、出血天数>7 d且血量>1.0定义为可接受性优、良、中、差;出血次数/记录周期数定义为出血率。分别于用药1~7年时进行子宫内膜细胞吸片检查。结果(1)95.60%的出血集中于第10~32 d之间,88.83%的出血天数在7 d之内,96.75%的出血量少于2.0。(2)4组间不同可接受程度出血的构成比有显著差别。G1、G3、G4接受性优的比例高于G2,G4接受性差的比例显著低于G1、G2、G3。(3)各组总体出血率分别为1 6.05%、59.03%、9.77%、30.66%,组间差异显著(P<0.05);出血率随用药时间延长而降低。(4)子宫内膜细胞吸片均未见恶性改变。结论低剂量雌激素加用天然黄体酮的出血率明显低于其他组;高剂量雌激素加用甲羟孕酮的出血率明显高于其他组;出血率随用药时间延长而降低;低剂量雌激素加用甲羟孕酮可能在控制出血天数和出血量方面效果较好;4种方案的内膜安全性均好。 Objective: To observe the influence of percutaneous estradiol and oral progestin on vaginal bleeding pattern in early postmenopausal Chinese women. Methods: A 7-year open, randomized, prospective study was designed. The cyclic-combined estrogen and progestin were used. The percutaneous estradiol (E2) was regarded as estrogen, while the micronized progesterone (MP) and medroxyprogesterone (MPA) served as progestin. 60 healthy women (naturally menopaused for 1 to 5 years) were recruited and divided into four groups. The regimen was as follows: (1) G1, percutaneous E2 1.5 mg/d plus oral MP 100mg/d. (2) G2, percutaneous E2 1.5 mg/d plus oral MPA 2 mg/d. (3)G3, percutaneous E2 0.75 mg/d plus oral MP 100 mg/d. (4) percutaneous E2 0.75 mg/d plus oral MPA 2 mg/d. Drugs were given for successive 25 days per cycle, and discontinued for 5 days. The beginning day, duration (days) and the amount of bleeding were recorded. The admissibility of vaginal bleeding was defined as follows: (1) superior admissibility: bleeding duration≤ 7 d and amount≤ 1.0. (2) reasonable admissibility: bleeding duration≤7 d and amount〉1.0. (3) moderate admissibility: bleeding duration〉 7 d and amount≤l. 0. (4) inferior admissibility: bleeding duration〉 7 d and amount〉 1.0. The bleeding rate was defined as the ratio of the frequency of bleeding to the number of recorded cycles. The endometrium biopsying by Pipella tube was conducted during 1-7 year. Results: 95.60% of vaginal bleeding happened on day 10 to day 32 of the cycle, while the bleeding lasting for less than 7 days accounted for 88. 83%. As regards the amount of bleeding, 96. 75% of bleedings were below 2. 0 and 55. 32% were below 1. 0. Significant difference was found in the admissibility between the 4 groups. than in G2, while the percentage of bleeding rate was 16.05%, 59.03% The percentage of superior admiss inferior admissibility in G4 was , 9.77% and 30.66%, in G1, ibility in G1, G3 and G4 was higher ower than in G1, G2 and G3. The G2, G3 and G4, respectively. There was a significant difference between the groups, with the highest rate in G2 and lowest in G3. The bleeding rate showed a descending tendency in course of therapy. The endometrium biopsy by Pipella tube showed no malignancy. Conclusions. The vaginal bleeding rate was lower in low-dose estradiol plus MP regimen than in other regimens while that of high-dose estradiol plus medroxyprogesterone was higher than others. The bleeding rate showed a descending tendency during the 7 years of treatment. The bleeding admissibility of G2 was inferior. The endometrium showed no malignancy in all 4 groups.
出处 《生殖医学杂志》 CAS 2010年第1期17-21,共5页 Journal of Reproductive Medicine
关键词 持续时间 子宫内膜 恶性肿瘤 雌激素 MPA 孕激素 雌二醇 周期数 Percutaneous estradiol Progestin Vaginal bleeding rate
  • 相关文献

参考文献10

  • 1Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesteroneacetate[J]. Obstet Gynecol, 1994,83 (5) :686-692.
  • 2James AS, James PS. Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxy progesterone acetate and conjugated equine estrogens[J]. Menopause, 2001,8 (5),321 -327.
  • 3Bewtra C, Kable WT, Gallqher JC. Endometrial histology and bleeding pattern in menopausal women treated with es trogen and continuous or cyclic progestin[J]. J Reprod Med, 1988,33(2) :205-208.
  • 4Rozenberg S, Ylikorkala O, Arrenbrecht S. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids[J]. Int J Fertil Womens Med, 1997,42pSuppl 2]:376-387.
  • 5路军丽,雷小敏,林守清,姜玉新,张颖.连续联合并用性激素补充疗法对子宫内膜的影响——最佳方案的探索[J].中国医刊,2002,37(10):24-26. 被引量:3
  • 6Ettinger B, Li DK, Klein R. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules [J]. Fertil Steril, 1998, 69 (5) :865-869.
  • 7Nand SL, Webster MA, Baber R, et al. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy[J]. Obstet Gynecol, 1998,91(5):678-684.
  • 8张忠兰,董振南,刘慧,刘建立.雌二醇皮贴与安宫黄体酮连续联合治疗改善绝经后症状及预防腰椎骨丢失的临床观察[J].生殖医学杂志,2002,11(5):274-278. 被引量:7
  • 9刘慧,张忠兰,彭红梅,刘建立,汪龙霞,王军燕.雌孕激素连续联合替代疗法对绝经后妇女阴道流血及子宫内膜的影响[J].生殖医学杂志,2002,11(3):135-139. 被引量:5
  • 10杨欣,郑淑蓉,白文佩,李辉,吴北生.结合雌激素加安宫黄体酮连续序贯应用治疗更年期综合征[J].北京医科大学学报,1996,28(6):464-466. 被引量:6

二级参考文献18

  • 1林守清 徐苓.女性生殖内分泌性激素补充疗法[M].北京:中国协和医科大学出版社,1999.36-136.
  • 2[1]Grady D Gebretsadik J, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a mata-analysis[J]. Obstet Gynecol,1995,85(2):304-313.
  • 3[2]Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone[J]. Am J Obstet Gynecol,1994,170(5):1213-1223.
  • 4[3]The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women[J]. JAMA,1996,275(5):370-375.
  • 5[4]Weintein L, Bewtra C, Gallagher JC, et al. Evaluation of continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient[J]. Am J Obstet Gynecol,1990,162(6):1534-1542.
  • 6[5]Doren M, Reuther G, Minne HW, et al. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women[J]. Am J Obstet Gynecol,1995,173(5):1446-1451.
  • 7[6]Archer DF, Pickar HJ, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate[J]. Obstet Gynecol,1994,83(5):585-692.
  • 8[7]Clishan PR, deZiegler D, Lozano K, et al. Comparison of sequential versus continuous estrogen and progestin replacement therapy in postmenopausal women[J]. Obstet Gynecol,1991,77(2):241-246.
  • 9[8]Rauch U, Taubert HD. Continuous hormone replacement therapy with estradiol valerate and cholrmadinone acetate in adjustable doses. A preliminary study[J]. Maturates,1993,17(2):123-127.
  • 10[9]Dmark IS, Jonsson B, Backstr MT, et al. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone or with 17 β-estradiol and norethindrone acetate[J]. Am J Obstet Gynecol,2001,184(6):1131-1138.

共引文献16

同被引文献21

  • 1Lethaby A,Farquhar C,Sarkis A,Roberts H,Jepson R,Barlow D,方爱华.绝经后妇女激素替代治疗:子宫内膜增生和不规则出血[J].生殖与避孕,2006,26(10):618-626. 被引量:4
  • 2North American Menopause Society. Estrogen and progestrogen use in postmenopausal women :2010 position statement of The North American Menopause Society[ J]. Menopause,2010,17:242-255.
  • 3De Villers TJ, Gass ML, Haines C J, et al. Global Consensus Statement on Menopausal Hormone Therapy [ J ]. Climacteric, 2013, 16 (2) :203-204.
  • 4Sturdee DW, Pines A. International Menopause Society Writing Group, et al. Pines on behalf of the International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health [ J ]. Climacteric, 2011,14(3) :302-320.
  • 5Rogerio A, Lobo MD, David F, et al. Role of progestogen in hormone therapy for postmenopausal women position statement of the North A- merican Menopause society [ J ]. Menopause, 2003,10 ( 2 ) : 113-132.
  • 6Maxson WS, Hargrove JT. Bioavailability of oral micronized progester- one[ J]. Fertility and Sterility,1985,44(5 ) :622-626.
  • 7de Villers TJ,Gass ML,Haines CJ,et al.Global Consensus Statement on Menopausal Hormone Therapy[J].Climacteric,2013,16(2):203-204.
  • 8王亚平,林守清,林中慧,陈蓉,张颖.口服两种剂量黄体酮胶丸的孕激素作用比较[J].中国实用妇科与产科杂志,2008,24(8):614-616. 被引量:4
  • 9徐秋霞,杨娟,王改玲.激素替代治疗围绝经期精神抑郁症疗效观察[J].中国医学创新,2009,6(33):51-51. 被引量:9
  • 10冯晓宇,于诗嘉,史铁梅.超声预测绝经后子宫内膜厚度≥5mm的女性患子宫内膜癌的风险[J].中国医学影像技术,2010,26(10):1940-1942. 被引量:7

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部